Glioma targeted therapy: insight into future of molecular approaches
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Glioma targeted therapy: insight into future of molecular approaches
Authors
Keywords
-
Journal
Molecular Cancer
Volume 21, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2022-02-08
DOI
10.1186/s12943-022-01513-z
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Inhibitory CD161 receptor identified in glioma-infiltrating T cells by single-cell analysis
- (2021) Nathan D. Mathewson et al. CELL
- LAG-3 expression in the inflammatory microenvironment of glioma
- (2021) Maximilian J. Mair et al. JOURNAL OF NEURO-ONCOLOGY
- CD8+CD161+ T-Cells: Cytotoxic Memory Cells With High Therapeutic Potential
- (2021) Vanaja Konduri et al. Frontiers in Immunology
- Hematopoietic stem cell gene therapy targeting TGFβ enhances the efficacy of irradiation therapy in a preclinical glioblastoma model
- (2021) Tereza Andreou et al. Journal for ImmunoTherapy of Cancer
- The Promising IgSF11 Immune Checkpoint Is Highly Expressed in Advanced Human Gliomas and Associates to Poor Prognosis
- (2021) Amina Ghouzlani et al. Frontiers in Oncology
- Tumor suppressor p53: Biology, signaling pathways, and therapeutic targeting
- (2021) Liz J. Hernández Borrero et al. BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER
- EGFR Activates a TAZ-driven Oncogenic Program in Glioblastoma.
- (2021) Minling Gao et al. CANCER RESEARCH
- Telomerase reverse transcriptase promoter mutation– and O6-methylguanine DNA methyltransferase promoter methylation–mediated sensitivity to temozolomide in isocitrate dehydrogenase–wild-type glioblastoma: is there a link?
- (2021) Dorothee Gramatzki et al. EUROPEAN JOURNAL OF CANCER
- Nose-to-brain co-delivery of drugs for glioblastoma treatment using nanostructured system
- (2021) Natália N. Ferreira et al. INTERNATIONAL JOURNAL OF PHARMACEUTICS
- Cancer-specific loss of TERT activation sensitizes glioblastoma to DNA damage
- (2021) Alexandra M. Amen et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- The Inhibition of B7H3 by 2-HG Accumulation Is Associated With Downregulation of VEGFA in IDH Mutated Gliomas
- (2021) Mengli Zhang et al. Frontiers in Cell and Developmental Biology
- Tumor cell IDO enhances immune suppression and decreases survival independent of tryptophan metabolism in glioblastoma
- (2021) Lijie Zhai et al. CLINICAL CANCER RESEARCH
- Regulatory mechanisms of immune checkpoints PD-L1 and CTLA-4 in cancer
- (2021) Hao Zhang et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- The 2021 WHO Classification of Tumors of the Central Nervous System: a summary
- (2021) David N Louis et al. NEURO-ONCOLOGY
- Heterogeneous delivery across the blood-brain barrier limits the efficacy of an EGFR-targeting antibody drug conjugate in glioblastoma
- (2021) Bianca-Maria Marin et al. NEURO-ONCOLOGY
- Mosaicism for Receptor Tyrosine Kinase Activation in a Glioblastoma Involving Both PDGFRA Amplification and NTRK2 Fusion
- (2021) Daniel J. Shepherd et al. ONCOLOGIST
- A Pan-Cancer Analysis of CD161, a Potential New Immune Checkpoint
- (2021) Xiaohan Zhou et al. Frontiers in Immunology
- Intracerebral administration of CTLA-4 and PD-1 immune checkpoint blocking monoclonal antibodies in patients with recurrent glioblastoma: a phase I clinical trial
- (2021) Johnny Duerinck et al. Journal for ImmunoTherapy of Cancer
- Pharmacological Approaches in Neurofibromatosis Type 1-Associated Nervous System Tumors
- (2021) Omar Rabab’h et al. Cancers
- MDM2/X Inhibitors as Radiosensitizers for Glioblastoma Targeted Therapy
- (2021) Xanthene Miles et al. Frontiers in Oncology
- Intratumor heterogeneity: the hidden barrier to immunotherapy against MSI tumors from the perspective of IFN-γ signaling and tumor-infiltrating lymphocytes
- (2021) Wantao Wu et al. Journal of Hematology & Oncology
- Neoadjuvant PD-1 blockade induces T cell and cDC1 activation but fails to overcome the immunosuppressive tumor associated macrophages in recurrent glioblastoma
- (2021) Alexander H. Lee et al. Nature Communications
- SPH3643: A novel CDK4/6 inhibitor with good anti‐cancer efficacy and strong blood‐brain barrier permeability
- (2020) XueMei Liao et al. CANCER SCIENCE
- Programmable base editing of mutated TERT promoter inhibits brain tumour growth
- (2020) Xinjian Li et al. NATURE CELL BIOLOGY
- A ”Clickable” Probe for Active MGMT in Glioblastoma Demonstrates Two Discrete Populations of MGMT
- (2020) Sudhir Raghavan et al. Cancers
- Osimertinib successfully combats EGFR-negative glioblastoma cells by inhibiting the MAPK pathway
- (2020) Cheng Chen et al. ACTA PHARMACOLOGICA SINICA
- A phase II open label, randomised study of ipilimumab with temozolomide versus temozolomide alone after surgery and chemoradiotherapy in patients with recently diagnosed glioblastoma: the Ipi-Glio trial protocol
- (2020) Nicholas F. Brown et al. BMC CANCER
- NRG/RTOG 1122: A phase 2, double‐blinded, placebo‐controlled study of bevacizumab with and without trebananib in patients with recurrent glioblastoma or gliosarcoma
- (2020) Eudocia Q. Lee et al. CANCER
- Blockade of CD73 delays glioblastoma growth by modulating the immune environment
- (2020) J. H. Azambuja et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Lower Grade Gliomas
- (2020) Gilbert Youssef et al. Current Neurology and Neuroscience Reports
- The CD47-SIRPα Immune Checkpoint
- (2020) Meike E.W. Logtenberg et al. IMMUNITY
- Phase 2 Study of a Temozolomide-Based Chemoradiation Therapy Regimen for High-Risk, Low-Grade Gliomas: Long-Term Results of Radiation Therapy Oncology Group 0424
- (2020) Barbara J. Fisher et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- PD-1 and BTLA regulate T cell signaling differentially and only partially through SHP1 and SHP2
- (2020) Xiaozheng Xu et al. JOURNAL OF CELL BIOLOGY
- Molecular markers and targeted therapy in pediatric low-grade glioma
- (2020) Peter de Blank et al. JOURNAL OF NEURO-ONCOLOGY
- A phase II randomized, multicenter, open-label trial of continuing adjuvant temozolomide beyond 6 cycles in patients with glioblastoma (GEINO 14-01)
- (2020) Carmen Balana et al. NEURO-ONCOLOGY
- Phase II study of oral mTOR inhibitor everolimus for recurrent, radiographic-progressive neurofibromatosis type 1-associated pediatric low-grade glioma A phase II study of continuous oral mTOR inhibitor everolimus for recurrent, radiographic-progressive neurofibromatosis type 1–associated pediatric low-grade glioma: a Neurofibromatosis Clinical Trials Consortium study
- (2020) Nicole J Ullrich et al. NEURO-ONCOLOGY
- Therapeutic modulation of phagocytosis in glioblastoma can activate both innate and adaptive antitumour immunity
- (2020) Christina A. von Roemeling et al. Nature Communications
- Phase I clinical trial of temsirolimus and perifosine for recurrent glioblastoma
- (2020) Thomas J. Kaley et al. Annals of Clinical and Translational Neurology
- Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma
- (2020) David A. Reardon et al. JAMA Oncology
- Enhanced B7-H4 expression in gliomas with low PD-L1 expression identifies super-cold tumors
- (2020) Di Chen et al. Journal for ImmunoTherapy of Cancer
- Epithelioid glioblastoma with microglia features: potential for novel therapy
- (2020) Nami Nakagomi et al. BRAIN PATHOLOGY
- Glioblastomas harboring gene fusions detected by next-generation sequencing
- (2020) Ha Young Woo et al. Brain Tumor Pathology
- Management of glioblastoma: State of the art and future directions
- (2020) Aaron C. Tan et al. CA-A CANCER JOURNAL FOR CLINICIANS
- How did lomustine become standard of care in recurrent glioblastoma?
- (2020) Michael Weller et al. CANCER TREATMENT REVIEWS
- Advanced Age Increases Immunosuppression in the Brain and Decreases Immunotherapeutic Efficacy in Subjects with Glioblastoma
- (2020) Erik Ladomersky et al. CLINICAL CANCER RESEARCH
- VISTA: an immune regulatory protein checking tumor and immune cells in cancer immunotherapy
- (2020) Xing Huang et al. Journal of Hematology & Oncology
- Discovery of AB680: A Potent and Selective Inhibitor of CD73
- (2020) Kenneth V. Lawson et al. JOURNAL OF MEDICINAL CHEMISTRY
- Retrospective analysis of combination carboplatin and vinblastine for pediatric low-grade glioma
- (2020) Anandani Nellan et al. JOURNAL OF NEURO-ONCOLOGY
- MGMT genomic rearrangements contribute to chemotherapy resistance in gliomas
- (2020) Barbara Oldrini et al. Nature Communications
- Immunosuppressive IDO in Cancer: Mechanisms of Action, Animal Models, and Targeting Strategies
- (2020) Lijie Zhai et al. Frontiers in Immunology
- Glioma patient profiling reveals the dominant immune suppressive adenosine axis is refractory to immune function restoration
- (2020) Martina Ott et al. JCI Insight
- Buparlisib plus carboplatin or lomustine in patients with recurrent glioblastoma: a phase Ib/II, open-label, multicentre, randomised study
- (2020) Mark Rosenthal et al. ESMO Open
- Phase I, open-label, multicentre study of buparlisib in combination with temozolomide or with concomitant radiation therapy and temozolomide in patients with newly diagnosed glioblastoma
- (2020) Patrick Yung Wen et al. ESMO Open
- 370MO FOLAGLI: A phase I study of folinic acid combined with temozolomide and radiotherapy to modulate MGMT gene promoter methylation in newly diagnosed MGMT non-methytated glioblastoma
- (2020) J-S. Frenel et al. ANNALS OF ONCOLOGY
- B7-H3: an attractive target for antibody-based immunotherapy
- (2020) Filippos Kontos et al. CLINICAL CANCER RESEARCH
- TGF-β1 modulates temozolomide resistance in glioblastoma via altered microRNA processing and elevated MGMT
- (2020) Er Nie et al. NEURO-ONCOLOGY
- Dissecting the immunosuppressive tumor microenvironments in Glioblastoma-on-a-Chip for optimized PD-1 immunotherapy
- (2020) Xin Cui et al. eLife
- Quantification of Bevacizumab Activity Following Treatment of Patients With Ovarian Cancer or Glioblastoma
- (2020) Christophe Lallemand et al. Frontiers in Immunology
- LAG-3: from molecular functions to clinical applications
- (2020) Takumi Maruhashi et al. Journal for ImmunoTherapy of Cancer
- Clinical Pharmacokinetics and Pharmacodynamics of Selumetinib
- (2020) Olivia Campagne et al. CLINICAL PHARMACOKINETICS
- Microglia are effector cells of CD47-SIRPα antiphagocytic axis disruption against glioblastoma
- (2019) Gregor Hutter et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Deciphering the complex role of thrombospondin-1 in glioblastoma development
- (2019) Thomas Daubon et al. Nature Communications
- Modulation of temozolomide dose differentially affects T-cell response to immune checkpoint inhibition
- (2019) Aida Karachi et al. NEURO-ONCOLOGY
- Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma
- (2019) Timothy F. Cloughesy et al. NATURE MEDICINE
- Neoadjuvant nivolumab modifies the tumor immune microenvironment in resectable glioblastoma
- (2019) Kurt A. Schalper et al. NATURE MEDICINE
- B7H3 regulates differentiation and serves as a potential biomarker and theranostic target for human glioblastoma
- (2019) Jingwen Zhang et al. LABORATORY INVESTIGATION
- A multicenter phase II study of temozolomide plus disulfiram and copper for recurrent temozolomide-resistant glioblastoma
- (2019) Jiayi Huang et al. JOURNAL OF NEURO-ONCOLOGY
- Targeted next-generation sequencing panel (TruSight Tumor 170) in diffuse glioma: a single institutional experience of 135 cases
- (2019) Kiyong Na et al. JOURNAL OF NEURO-ONCOLOGY
- Eribulin penetrates brain tumor tissue and prolongs survival of mice harboring intracerebral glioblastoma xenografts
- (2019) Masamichi Takahashi et al. CANCER SCIENCE
- The third-generation EGFR inhibitor AZD9291 overcomes primary resistance by continuously blocking ERK signaling in glioblastoma
- (2019) Xuejiao Liu et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Selumetinib in paediatric patients with BRAF-aberrant or neurofibromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma: a multicentre, phase 2 trial
- (2019) Jason Fangusaro et al. LANCET ONCOLOGY
- Control of tumor-associated macrophages and T cells in glioblastoma via AHR and CD39
- (2019) Maisa C. Takenaka et al. NATURE NEUROSCIENCE
- A Phase 0 Trial of Ribociclib in Recurrent Glioblastoma Patients Incorporating a Tumor Pharmacodynamic- and Pharmacokinetic-Guided Expansion Cohort
- (2019) An-Chi Tien et al. CLINICAL CANCER RESEARCH
- Phase 1 study of the MDM2 inhibitor AMG 232 in patients with advanced P53 wild-type solid tumors or multiple myeloma
- (2019) W. Larry Gluck et al. INVESTIGATIONAL NEW DRUGS
- MET in glioma: signaling pathways and targeted therapies
- (2019) Fangling Cheng et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Phase II study of Dovitinib in recurrent glioblastoma
- (2019) Mayur Sharma et al. JOURNAL OF NEURO-ONCOLOGY
- Epidermal growth factor receptor (EGFR) amplification rates observed in screening patients for randomized trials in glioblastoma
- (2019) Andrew B. Lassman et al. JOURNAL OF NEURO-ONCOLOGY
- Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma
- (2019) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Quantitative Interactomics in Primary T Cells Provides a Rationale for Concomitant PD-1 and BTLA Coinhibitor Blockade in Cancer Immunotherapy
- (2019) Javier Celis-Gutierrez et al. Cell Reports
- Bortezomib administered prior to temozolomide depletes MGMT, chemosensitizes glioblastoma with unmethylated MGMT promoter and prolongs animal survival
- (2019) Mohummad Aminur Rahman et al. BRITISH JOURNAL OF CANCER
- Therapeutic targeting of TGF-βligands in glioblastoma using novel antisense oligonucleotides reduces the growth of experimental gliomas
- (2019) Alexandros Papachristodoulou et al. CLINICAL CANCER RESEARCH
- Nasal Administration of Cationic Nanoemulsions as CD73-siRNA Delivery System for Glioblastoma Treatment: a New Therapeutical Approach
- (2019) J. H. Azambuja et al. MOLECULAR NEUROBIOLOGY
- Phase II trial of ponatinib in patients with bevacizumab‐refractory glioblastoma
- (2019) Eudocia Q. Lee et al. Cancer Medicine
- B7-H3-redirected chimeric antigen receptor T cells target glioblastoma and neurospheres
- (2019) Dean Nehama et al. EBioMedicine
- BRAF Mutations and the Utility of RAF and MEK Inhibitors in Primary Brain Tumors
- (2019) Karisa C. Schreck et al. Cancers
- Phase I/II study of bevacizumab with BKM120, an oral PI3K inhibitor, in patients with refractory solid tumors (phase I) and relapsed/refractory glioblastoma (phase II)
- (2019) John D. Hainsworth et al. JOURNAL OF NEURO-ONCOLOGY
- Tumor pharmacokinetics and pharmacodynamics of the CDK4/6 inhibitor ribociclib in patients with recurrent glioblastoma
- (2019) Todd W. Miller et al. JOURNAL OF NEURO-ONCOLOGY
- Efficacy of initial temozolomide for high-risk low grade gliomas in a phase II AINO (Italian Association for Neuro-Oncology) study: a post-hoc analysis within molecular subgroups of WHO 2016
- (2019) Roberta Rudà et al. JOURNAL OF NEURO-ONCOLOGY
- A Phase Ib/II, open-label, multicenter study of INC280 (capmatinib) alone and in combination with buparlisib (BKM120) in adult patients with recurrent glioblastoma
- (2019) Martin van den Bent et al. JOURNAL OF NEURO-ONCOLOGY
- CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2012–2016
- (2019) Quinn T Ostrom et al. NEURO-ONCOLOGY
- A phase 2 study of trametinib for patients with pediatric glioma or plexiform neurofibroma with refractory tumor and activation of the MAPK/ERK pathway: TRAM-01
- (2019) Sébastien Perreault et al. BMC CANCER
- Efficacy and Safety of Dabrafenib in Pediatric Patients with BRAF V600 Mutation–Positive Relapsed or Refractory Low-Grade Glioma: Results from a Phase I/IIa Study
- (2019) Darren R. Hargrave et al. CLINICAL CANCER RESEARCH
- Targeting the ubiquitin-proteasome pathway to overcome anti-cancer drug resistance
- (2019) Silpa Narayanan et al. DRUG RESISTANCE UPDATES
- PD-L1 Expression in Pediatric Low-Grade Gliomas Is Independent of BRAF V600E Mutational Status
- (2019) Allison M Martin et al. JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY
- Immune profiling of human tumors identifies CD73 as a combinatorial target in glioblastoma
- (2019) Sangeeta Goswami et al. NATURE MEDICINE
- The DNA methylome of DDR genes and benefit from RT or TMZ in IDH mutant low-grade glioma treated in EORTC 22033
- (2018) Pierre Bady et al. ACTA NEUROPATHOLOGICA
- Genetic and clinical characterization of B7-H3(CD276) expression and epigenetic regulation in diffuse brain glioma
- (2018) Zhiliang Wang et al. CANCER SCIENCE
- Disrupting CD47-SIRPα axis alone or combined with autophagy depletion for the therapy of glioblastoma
- (2018) Xuyao Zhang et al. CARCINOGENESIS
- IDO1 in cancer: a Gemini of immune checkpoints
- (2018) Lijie Zhai et al. Cellular & Molecular Immunology
- IDO1 Inhibition Synergizes with Radiation and PD-1 Blockade to Durably Increase Survival Against Advanced Glioblastoma
- (2018) Erik Ladomersky et al. CLINICAL CANCER RESEARCH
- Phase 0 Trial of AZD1775 in First-Recurrence Glioblastoma Patients
- (2018) Nader Sanai et al. CLINICAL CANCER RESEARCH
- Therapeutic Immune Modulation Against Solid Cancers with Intratumoral Poly-ICLC: A Pilot Trial
- (2018) Chrisann Kyi et al. CLINICAL CANCER RESEARCH
- Phase 2 Study of Bortezomib Combined With Temozolomide and Regional Radiation Therapy for Upfront Treatment of Patients With Newly Diagnosed Glioblastoma Multiforme: Safety and Efficacy Assessment
- (2018) Xiao-Tang Kong et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic BRAF V600–Mutant Anaplastic Thyroid Cancer
- (2018) Vivek Subbiah et al. JOURNAL OF CLINICAL ONCOLOGY
- Final results of a phase I dose-escalation, dose-expansion study of adding disulfiram with or without copper to adjuvant temozolomide for newly diagnosed glioblastoma
- (2018) Jiayi Huang et al. JOURNAL OF NEURO-ONCOLOGY
- Targetable Gene Fusions Associate With the IDH Wild-Type Astrocytic Lineage in Adult Gliomas
- (2018) Sherise D Ferguson et al. JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY
- Concurrent BRAF/MEK Inhibitors in BRAF V600–Mutant High-Grade Primary Brain Tumors
- (2018) Karisa C. Schreck et al. Journal of the National Comprehensive Cancer Network
- DNA methylation-based classification of central nervous system tumours
- (2018) David Capper et al. NATURE
- OUP accepted manuscript
- (2018) NEURO-ONCOLOGY
- Phase II Study to Evaluate the Efficacy and Safety of Rilotumumab and Bevacizumab in Subjects with Recurrent Malignant Glioma
- (2018) Mary Lou Affronti et al. ONCOLOGIST
- CD47 promotes human glioblastoma invasion through activation of PI3K/Akt pathway
- (2018) Xuejian Liu et al. ONCOLOGY RESEARCH
- A radiosensitivity gene signature and PD-L1 predict the clinical outcomes of patients with lower grade glioma in TCGA
- (2018) Bum-Sup Jang et al. RADIOTHERAPY AND ONCOLOGY
- Structural absorption by barbule microstructures of super black bird of paradise feathers
- (2018) Dakota E. McCoy et al. Nature Communications
- Association of MGMT Promoter Methylation Status With Survival Outcomes in Patients With High-Risk Glioma Treated With Radiotherapy and Temozolomide
- (2018) Erica H. Bell et al. JAMA Oncology
- PD-1 ( PDCD1 ) Promoter Methylation Is a Prognostic Factor in Patients With Diffuse Lower-Grade Gliomas Harboring Isocitrate Dehydrogenase ( IDH ) Mutations
- (2018) Lea Kristin Röver et al. EBioMedicine
- Expression of LAG-3 and efficacy of combination treatment with anti-LAG-3 and anti-PD-1 monoclonal antibodies in glioblastoma
- (2018) Sarah Harris-Bookman et al. INTERNATIONAL JOURNAL OF CANCER
- Clinical activity and safety of atezolizumab in patients with recurrent glioblastoma
- (2018) Rimas V. Lukas et al. JOURNAL OF NEURO-ONCOLOGY
- Phase-2 trial of palbociclib in adult patients with recurrent RB1-positive glioblastoma
- (2018) Jennie W. Taylor et al. JOURNAL OF NEURO-ONCOLOGY
- Primary brain tumours in adults
- (2018) Sarah Lapointe et al. LANCET
- MGMT promoter methylation status testing to guide therapy for glioblastoma: refining the approach based on emerging evidence and current challenges
- (2018) Alireza Mansouri et al. NEURO-ONCOLOGY
- P01.052 Updated results of the INTELLANCE 2/EORTC trial 1410 randomized phase II study on Depatux -M alone, Depatux-M in combination with temozolomide (TMZ) and either TMZ or lomustine (LOM) in recurrent EGFR amplified glioblastoma (NCT02343406)
- (2018) M van den Bent et al. NEURO-ONCOLOGY
- OUP accepted manuscript
- (2018) NEURO-ONCOLOGY
- Dendritic cell vaccines for high-grade gliomas
- (2018) Matthew Eagles et al. Therapeutics and Clinical Risk Management
- Akt and mTORC1 signaling as predictive biomarkers for the EGFR antibody nimotuzumab in glioblastoma
- (2018) Michael W. Ronellenfitsch et al. Acta Neuropathologica Communications
- Genetic, epigenetic and immunologic profiling of MMR-deficient relapsed glioblastoma
- (2018) Stefano Indraccolo et al. CLINICAL CANCER RESEARCH
- BRAF Inhibition in BRAFV600-Mutant Gliomas: Results From the VE-BASKET Study
- (2018) Thomas Kaley et al. JOURNAL OF CLINICAL ONCOLOGY
- Tim-3 and its role in regulating anti-tumor immunity
- (2017) Madhumita Das et al. IMMUNOLOGICAL REVIEWS
- Potential targeting of B7-H4 for the treatment of cancer
- (2017) Joseph R. Podojil et al. IMMUNOLOGICAL REVIEWS
- Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma
- (2017) Roger Stupp et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- CNS Tumors in Neurofibromatosis
- (2017) Jian Campian et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Study of Onartuzumab Plus Bevacizumab Versus Placebo Plus Bevacizumab in Patients With Recurrent Glioblastoma: Efficacy, Safety, and Hepatocyte Growth Factor and O6-Methylguanine–DNA Methyltransferase Biomarker Analyses
- (2017) Timothy Cloughesy et al. JOURNAL OF CLINICAL ONCOLOGY
- Adult Glioblastoma
- (2017) Brian M. Alexander et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I trial of aflibercept (VEGF trap) with radiation therapy and concomitant and adjuvant temozolomide in patients with high-grade gliomas
- (2017) Lakshmi Nayak et al. JOURNAL OF NEURO-ONCOLOGY
- A phase II trial of autologous dendritic cell vaccination and radiochemotherapy following fluorescence-guided surgery in newly diagnosed glioblastoma patients
- (2017) Susana Inogés et al. Journal of Translational Medicine
- Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial
- (2017) Michael Weller et al. LANCET ONCOLOGY
- European Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas
- (2017) Michael Weller et al. LANCET ONCOLOGY
- Recent advances in the use of PI3K inhibitors for glioblastoma multiforme: current preclinical and clinical development
- (2017) Hua-fu Zhao et al. Molecular Cancer
- Phase II trial of dacomitinib, a pan–human EGFR tyrosine kinase inhibitor, in recurrent glioblastoma patients with EGFR amplification
- (2017) Juan Manuel Sepúlveda-Sánchez et al. NEURO-ONCOLOGY
- Phase II study of cabozantinib in patients with progressive glioblastoma: subset analysis of patients with prior antiangiogenic therapy
- (2017) Timothy F Cloughesy et al. NEURO-ONCOLOGY
- A phase I trial of the MEK inhibitor selumetinib (AZD6244) in pediatric patients with recurrent or refractory low-grade glioma: a Pediatric Brain Tumor Consortium (PBTC) study
- (2017) Anuradha Banerjee et al. NEURO-ONCOLOGY
- Phase II study of cabozantinib in patients with progressive glioblastoma: subset analysis of patients naive to antiangiogenic therapy
- (2017) Patrick Y Wen et al. NEURO-ONCOLOGY
- CD70, a novel target of CAR T-cell therapy for gliomas
- (2017) Linchun Jin et al. NEURO-ONCOLOGY
- Lomustine and Bevacizumab in Progressive Glioblastoma
- (2017) Wolfgang Wick et al. NEW ENGLAND JOURNAL OF MEDICINE
- Disrupting the CD47-SIRPα anti-phagocytic axis by a humanized anti-CD47 antibody is an efficacious treatment for malignant pediatric brain tumors
- (2017) Sharareh Gholamin et al. Science Translational Medicine
- A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma
- (2017) Donald M. O’Rourke et al. Science Translational Medicine
- Blocking the CD47-SIRPα axis by delivery of anti-CD47 antibody induces antitumor effects in glioma and glioma stem cells
- (2017) Feng Li et al. OncoImmunology
- Blockade of Tim-3 binding to phosphatidylserine and CEACAM1 is a shared feature of anti-Tim-3 antibodies that have functional efficacy
- (2017) Catherine A. Sabatos-Peyton et al. OncoImmunology
- Molecular and clinical characterization of TIM-3 in glioma through 1,024 samples
- (2017) Guanzhang Li et al. OncoImmunology
- Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma
- (2017) Sith Sathornsumetee et al. NEURO-ONCOLOGY
- The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary
- (2016) David N. Louis et al. ACTA NEUROPATHOLOGICA
- Nonrandomized comparison of neurofibromatosis type 1 and non-neurofibromatosis type 1 children who received carboplatin and vincristine for progressive low-grade glioma: A report from the Children's Oncology Group
- (2016) Joann L. Ater et al. CANCER
- Disease progression in recurrent glioblastoma patients treated with the VEGFR inhibitor axitinib is associated with increased regulatory T cell numbers and T cell exhaustion
- (2016) Stephanie Du Four et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Adenosine 2B Receptor Expression on Cancer Cells Promotes Metastasis
- (2016) D. Mittal et al. CANCER RESEARCH
- Identification of Patients with Recurrent Glioblastoma Who May Benefit from Combined Bevacizumab and CCNU Therapy: A Report from the BELOB Trial
- (2016) L. Erdem-Eraslan et al. CANCER RESEARCH
- Vaccination with Irradiated Autologous Tumor Cells Mixed with Irradiated GM-K562 Cells Stimulates Antitumor Immunity and T Lymphocyte Activation in Patients with Recurrent Malignant Glioma
- (2016) W. T. Curry et al. CLINICAL CANCER RESEARCH
- Phase II Study of Radiotherapy and Temsirolimus versus Radiochemotherapy with Temozolomide in Patients with Newly Diagnosed Glioblastoma without MGMT Promoter Hypermethylation (EORTC 26082)
- (2016) W. Wick et al. CLINICAL CANCER RESEARCH
- Combination Therapy with Anti-PD-1, Anti-TIM-3, and Focal Radiation Results in Regression of Murine Gliomas
- (2016) Jennifer E. Kim et al. CLINICAL CANCER RESEARCH
- RB1: a prototype tumor suppressor and an enigma
- (2016) Nicholas J. Dyson GENES & DEVELOPMENT
- Phase II Weekly Vinblastine for Chemotherapy-Naïve Children With Progressive Low-Grade Glioma: A Canadian Pediatric Brain Tumor Consortium Study
- (2016) Alvaro Lassaletta et al. JOURNAL OF CLINICAL ONCOLOGY
- Immune Checkpoint Inhibition for Hypermutant Glioblastoma Multiforme Resulting From Germline Biallelic Mismatch Repair Deficiency
- (2016) Eric Bouffet et al. JOURNAL OF CLINICAL ONCOLOGY
- Immune phenotypes predict survival in patients with glioblastoma multiforme
- (2016) Haouraa Mostafa et al. Journal of Hematology & Oncology
- Defining the cutoff value of MGMT gene promoter methylation and its predictive capacity in glioblastoma
- (2016) Giovanni Brigliadori et al. JOURNAL OF NEURO-ONCOLOGY
- Phase II study of tivozanib, an oral VEGFR inhibitor, in patients with recurrent glioblastoma
- (2016) Jayashree Kalpathy-Cramer et al. JOURNAL OF NEURO-ONCOLOGY
- NRG oncology RTOG 0625: a randomized phase II trial of bevacizumab with either irinotecan or dose-dense temozolomide in recurrent glioblastoma
- (2016) Mark R. Gilbert et al. JOURNAL OF NEURO-ONCOLOGY
- A randomized phase II trial of standard dose bevacizumab versus low dose bevacizumab plus lomustine (CCNU) in adults with recurrent glioblastoma
- (2016) Shiao-Pei Weathers et al. JOURNAL OF NEURO-ONCOLOGY
- Cilengitide with metronomic temozolomide, procarbazine, and standard radiotherapy in patients with glioblastoma and unmethylated MGMT gene promoter in ExCentric, an open-label phase II trial
- (2016) Mustafa Khasraw et al. JOURNAL OF NEURO-ONCOLOGY
- Pembrolizumab: first experience with recurrent primary central nervous system (CNS) tumors
- (2016) Deborah T. Blumenthal et al. JOURNAL OF NEURO-ONCOLOGY
- Synergistic antitumor effect with indoleamine 2,3-dioxygenase inhibition and temozolomide in a murine glioma model
- (2016) Mitsuto Hanihara et al. JOURNAL OF NEUROSURGERY
- Vemurafenib in patients with BRAFV600E-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial
- (2016) Marcia S Brose et al. LANCET ONCOLOGY
- Health-related quality of life in patients with high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study
- (2016) Jaap C Reijneveld et al. LANCET ONCOLOGY
- Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study
- (2016) Brigitta G Baumert et al. LANCET ONCOLOGY
- Dabrafenib plus trametinib in patients with previously treated BRAF V600E -mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial
- (2016) David Planchard et al. LANCET ONCOLOGY
- Rapid Conversion of Mutant IDH1 from Driver to Passenger in a Model of Human Gliomagenesis
- (2016) T.-C. A. Johannessen et al. MOLECULAR CANCER RESEARCH
- The role of microglia and macrophages in glioma maintenance and progression
- (2016) Dolores Hambardzumyan et al. NATURE NEUROSCIENCE
- A Phase II randomized study of galunisertib monotherapy or galunisertib plus lomustine compared with lomustine monotherapy in patients with recurrent glioblastoma
- (2016) Alba A. Brandes et al. NEURO-ONCOLOGY
- Autocrine VEGFR1 and VEGFR2 signaling promotes survival in human glioblastoma models in vitro and in vivo
- (2016) Emese Szabo et al. NEURO-ONCOLOGY
- Radiation plus Procarbazine, CCNU, and Vincristine in Low-Grade Glioma
- (2016) Jan C. Buckner et al. NEW ENGLAND JOURNAL OF MEDICINE
- The tumor microenvironment underlies acquired resistance to CSF-1R inhibition in gliomas
- (2016) D. F. Quail et al. SCIENCE
- Immunogenomics of Hypermutated Glioblastoma: A Patient with Germline POLE Deficiency Treated with Checkpoint Blockade Immunotherapy
- (2016) T. M. Johanns et al. Cancer Discovery
- Cilengitide in newly diagnosed glioblastoma: biomarker expression and outcome
- (2016) Michael Weller et al. Oncotarget
- Anti-CD47 Treatment Stimulates Phagocytosis of Glioblastoma by M1 and M2 Polarized Macrophages and Promotes M1 Polarized Macrophages In Vivo
- (2016) Michael Zhang et al. PLoS One
- IDH mutation status and role of WHO grade and mitotic index in overall survival in grade II–III diffuse gliomas
- (2015) Adriana Olar et al. ACTA NEUROPATHOLOGICA
- B7-H3 ameliorates GVHD
- (2015) P. Steinberger BLOOD
- B7-H3 expression in donor T cells and host cells negatively regulates acute graft-versus-host disease lethality
- (2015) R. G. Veenstra et al. BLOOD
- Detection, Characterization, and Inhibition of FGFR-TACC Fusions in IDH Wild-type Glioma
- (2015) A. L. Di Stefano et al. CLINICAL CANCER RESEARCH
- Patients With Proneural Glioblastoma May Derive Overall Survival Benefit From the Addition of Bevacizumab to First-Line Radiotherapy and Temozolomide: Retrospective Analysis of the AVAglio Trial
- (2015) Thomas Sandmann et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I Dose-Escalation Study of JNJ-42756493, an Oral Pan–Fibroblast Growth Factor Receptor Inhibitor, in Patients With Advanced Solid Tumors
- (2015) Josep Tabernero et al. JOURNAL OF CLINICAL ONCOLOGY
- Survival impact of time to initiation of chemoradiotherapy after resection of newly diagnosed glioblastoma
- (2015) Matthew Z. Sun et al. JOURNAL OF NEUROSURGERY
- CD47 blockade triggers T cell–mediated destruction of immunogenic tumors
- (2015) Xiaojuan Liu et al. NATURE MEDICINE
- A phase I study of cediranib in combination with cilengitide in patients with recurrent glioblastoma
- (2015) Elizabeth R. Gerstner et al. NEURO-ONCOLOGY
- A phase II, multicenter trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma: the ACT III study
- (2015) J. Schuster et al. NEURO-ONCOLOGY
- Two cilengitide regimens in combination with standard treatment for patients with newly diagnosed glioblastoma and unmethylated MGMT gene promoter: results of the open-label, controlled, randomized phase II CORE study
- (2015) L. Burt Nabors et al. NEURO-ONCOLOGY
- Diagnostic, prognostic and predictive relevance of molecular markers in gliomas
- (2015) Sebastian Brandner et al. NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY
- Tissue-based map of the human proteome
- (2015) M. Uhlen et al. SCIENCE
- Rational development and characterization of humanized anti–EGFR variant III chimeric antigen receptor T cells for glioblastoma
- (2015) Laura A. Johnson et al. Science Translational Medicine
- Radiation Therapy Oncology Group 9802: Controversy or Consensus in the Treatment of Newly Diagnosed Low-Grade Glioma?
- (2015) Nadia N. Laack et al. SEMINARS IN RADIATION ONCOLOGY
- Durable Therapeutic Efficacy Utilizing Combinatorial Blockade against IDO, CTLA-4, and PD-L1 in Mice with Brain Tumors
- (2014) D. A. Wainwright et al. CLINICAL CANCER RESEARCH
- Glioma-associated microglial MMP9 expression is upregulated by TLR2 signaling and sensitive to minocycline
- (2014) Feng Hu et al. INTERNATIONAL JOURNAL OF CANCER
- Coinhibitory receptor PD-1H preferentially suppresses CD4+ T cell–mediated immunity
- (2014) Dallas B. Flies et al. JOURNAL OF CLINICAL INVESTIGATION
- Cilengitide treatment of newly diagnosed glioblastoma patients does not alter patterns of progression
- (2014) Günter Eisele et al. JOURNAL OF NEURO-ONCOLOGY
- Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial
- (2014) Roger Stupp et al. LANCET ONCOLOGY
- Phase II study of sorafenib in children with recurrent or progressive low-grade astrocytomas
- (2014) M. A. Karajannis et al. NEURO-ONCOLOGY
- A phase II trial of everolimus, temozolomide, and radiotherapy in patients with newly diagnosed glioblastoma: NCCTG N057K
- (2014) Daniel J. Ma et al. NEURO-ONCOLOGY
- A Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma
- (2014) Mark R. Gilbert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Bevacizumab plus Radiotherapy–Temozolomide for Newly Diagnosed Glioblastoma
- (2014) Olivier L. Chinot et al. NEW ENGLAND JOURNAL OF MEDICINE
- Vaccination with dendritic cells loaded with allogeneic brain tumor cells for recurrent malignant brain tumors induces a CD4+IL17+ response
- (2014) Michael R Olin et al. Journal for ImmunoTherapy of Cancer
- Therapeutic vaccination against autologous cancer stem cells with mRNA-transfected dendritic cells in patients with glioblastoma
- (2013) Einar Osland Vik-Mo et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- The Somatic Genomic Landscape of Glioblastoma
- (2013) Cameron W. Brennan et al. CELL
- Targeting CD73 Enhances the Antitumor Activity of Anti-PD-1 and Anti-CTLA-4 mAbs
- (2013) B. Allard et al. CLINICAL CANCER RESEARCH
- A Phase I/II Trial of Pazopanib in Combination with Lapatinib in Adult Patients with Relapsed Malignant Glioma
- (2013) D. A. Reardon et al. CLINICAL CANCER RESEARCH
- Phase III Randomized Trial Comparing the Efficacy of Cediranib As Monotherapy, and in Combination With Lomustine, Versus Lomustine Alone in Patients With Recurrent Glioblastoma
- (2013) Tracy T. Batchelor et al. JOURNAL OF CLINICAL ONCOLOGY
- Intratumoral IL-12 combined with CTLA-4 blockade elicits T cell–mediated glioma rejection
- (2013) Johannes vom Berg et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Comparison of Glioma-associated Antigen Peptide-loaded Versus Autologous Tumor Lysate-loaded Dendritic Cell Vaccination in Malignant Glioma Patients
- (2013) Robert M. Prins et al. JOURNAL OF IMMUNOTHERAPY
- CSF-1R inhibition alters macrophage polarization and blocks glioma progression
- (2013) Stephanie M Pyonteck et al. NATURE MEDICINE
- Synergy between the ectoenzymes CD39 and CD73 contributes to adenosinergic immunosuppression in human malignant gliomas
- (2013) Shuo Xu et al. NEURO-ONCOLOGY
- Phase II study of cilengitide in the treatment of refractory or relapsed high-grade gliomas in children: A report from the Children's Oncology Group
- (2013) T. J. MacDonald et al. NEURO-ONCOLOGY
- Improved tumor oxygenation and survival in glioblastoma patients who show increased blood perfusion after cediranib and chemoradiation
- (2013) T. T. Batchelor et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal
- (2013) P. J. Killela et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Anti-CD47 antibody-mediated phagocytosis of cancer by macrophages primes an effective antitumor T-cell response
- (2013) D. Tseng et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- TERT Promoter Mutations in Familial and Sporadic Melanoma
- (2013) S. Horn et al. SCIENCE
- An Inhibitor of Mutant IDH1 Delays Growth and Promotes Differentiation of Glioma Cells
- (2013) D. Rohle et al. SCIENCE
- B7-H4 expression is elevated in human U251 glioma stem-like cells and is inducible in monocytes cultured with U251 stem-like cell conditioned medium
- (2013) Lian-Jie Mo et al. Chinese Journal of Cancer
- Targeted therapy with bevacizumab and erlotinib tailored to the molecular profile of patients with recurrent glioblastoma. Preliminary experience
- (2012) Quintino Giorgio D’Alessandris et al. ACTA NEUROCHIRURGICA
- Phase I trial of a multi-epitope-pulsed dendritic cell vaccine for patients with newly diagnosed glioblastoma
- (2012) Surasak Phuphanich et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Targeting of a Conformationally Exposed, Tumor-Specific Epitope of EGFR as a Strategy for Cancer Therapy
- (2012) H. K. Gan et al. CANCER RESEARCH
- CD27 Signaling Increases the Frequency of Regulatory T Cells and Promotes Tumor Growth
- (2012) C. Claus et al. CANCER RESEARCH
- Comparison of a Strategy Favoring Early Surgical Resection vs a Strategy Favoring Watchful Waiting in Low-Grade Gliomas
- (2012) Asgeir S. Jakola et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- 5′-ectonucleotidase mediates multiple-drug resistance in glioblastoma multiforme cells
- (2012) Claudia Quezada et al. JOURNAL OF CELLULAR PHYSIOLOGY
- Unknown
- (2012) Salvatore Coniglio et al. MOLECULAR MEDICINE
- A feasibility and efficacy study of rapamycin and erlotinib for recurrent pediatric low-grade glioma (LGG)
- (2012) Michal Yalon et al. PEDIATRIC BLOOD & CANCER
- Transforming Fusions of FGFR and TACC Genes in Human Glioblastoma
- (2012) D. Singh et al. SCIENCE
- Increased Survival of Glioblastoma Patients Who Respond to Antiangiogenic Therapy with Elevated Blood Perfusion
- (2011) A. G. Sorensen et al. CANCER RESEARCH
- Myeloid Biomarkers Associated with Glioblastoma Response to Anti-VEGF Therapy with Aflibercept
- (2011) J. F. de Groot et al. CLINICAL CANCER RESEARCH
- Costimulatory Protein 4IgB7H3 Drives the Malignant Phenotype of Glioblastoma by Mediating Immune Escape and Invasiveness
- (2011) D. Lemke et al. CLINICAL CANCER RESEARCH
- Phase II Study of Aflibercept in Recurrent Malignant Glioma: A North American Brain Tumor Consortium Study
- (2011) John F. de Groot et al. JOURNAL OF CLINICAL ONCOLOGY
- VISTA, a novel mouse Ig superfamily ligand that negatively regulates T cell responses
- (2011) Li Wang et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Immune Response in Patients With Newly Diagnosed Glioblastoma Multiforme Treated With Intranodal Autologous Tumor Lysate-dendritic Cell Vaccination After Radiation Chemotherapy
- (2011) Camilo E. Fadul et al. JOURNAL OF IMMUNOTHERAPY
- A multicenter phase I trial of combination therapy with interferon-β and temozolomide for high-grade gliomas (INTEGRA study): the final report
- (2011) Toshihiko Wakabayashi et al. JOURNAL OF NEURO-ONCOLOGY
- Cilengitide in patients with recurrent glioblastoma: the results of NABTC 03-02, a phase II trial with measures of treatment delivery
- (2011) Mark R. Gilbert et al. JOURNAL OF NEURO-ONCOLOGY
- Phase II trial of vorinostat in combination with bortezomib in recurrent glioblastoma: a north central cancer treatment group study
- (2011) B. B. Friday et al. NEURO-ONCOLOGY
- A phase II study evaluating the efficacy and safety of AMG 102 (rilotumumab) in patients with recurrent glioblastoma
- (2011) P. Y. Wen et al. NEURO-ONCOLOGY
- Propentofylline decreases tumor growth in a rodent model of glioblastoma multiforme by a direct mechanism on microglia
- (2011) V. L. Jacobs et al. NEURO-ONCOLOGY
- Characteristics of the Alternative Phenotype of Microglia/Macrophages and its Modulation in Experimental Gliomas
- (2011) Konrad Gabrusiewicz et al. PLoS One
- Hepatocyte growth factor (HGF) autocrine activation predicts sensitivity to MET inhibition in glioblastoma
- (2011) Q. Xie et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- A phase 2 trial of single-agent bevacizumab given in an every-3-week schedule for patients with recurrent high-grade gliomas
- (2010) Jeffrey J. Raizer et al. CANCER
- Activation of CD47 receptors causes proliferation of human astrocytoma but not normal astrocytes via an Akt-dependent pathway
- (2010) Emilie Sick et al. GLIA
- Phase I/IIa Study of Cilengitide and Temozolomide With Concomitant Radiotherapy Followed by Cilengitide and Temozolomide Maintenance Therapy in Patients With Newly Diagnosed Glioblastoma
- (2010) Roger Stupp et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Study of Cediranib, an Oral Pan–Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Recurrent Glioblastoma
- (2010) Tracy T. Batchelor et al. JOURNAL OF CLINICAL ONCOLOGY
- Induction of CD8+ T-Cell Responses Against Novel Glioma–Associated Antigen Peptides and Clinical Activity by Vaccinations With α-Type 1 Polarized Dendritic Cells and Polyinosinic-Polycytidylic Acid Stabilized by Lysine and Carboxymethylcellulose in Patients With Recurrent Malignant Glioma
- (2010) Hideho Okada et al. JOURNAL OF CLINICAL ONCOLOGY
- Bevacizumab salvage therapy following progression in high-grade glioma patients treated with VEGF receptor tyrosine kinase inhibitors
- (2010) B. J. Scott et al. NEURO-ONCOLOGY
- Phase II trial of pazopanib (GW786034), an oral multi-targeted angiogenesis inhibitor, for adults with recurrent glioblastoma (North American Brain Tumor Consortium Study 06-02)
- (2010) F. M. Iwamoto et al. NEURO-ONCOLOGY
- Targeted therapy for high-grade glioma with the TGF- 2 inhibitor trabedersen: results of a randomized and controlled phase IIb study
- (2010) U. Bogdahn et al. NEURO-ONCOLOGY
- Phase III randomized trial of CED of IL13-PE38QQR vs Gliadel wafers for recurrent glioblastoma
- (2010) S. Kunwar et al. NEURO-ONCOLOGY
- Stratified phase II trial of cetuximab in patients with recurrent high-grade glioma
- (2009) B. Neyns et al. ANNALS OF ONCOLOGY
- Two phase II trials of temozolomide with interferon-α2b (pegylated and non-pegylated) in patients with recurrent glioblastoma multiforme
- (2009) M D Groves et al. BRITISH JOURNAL OF CANCER
- Metronomic chemotherapy with daily, oral etoposide plus bevacizumab for recurrent malignant glioma: a phase II study
- (2009) D A Reardon et al. BRITISH JOURNAL OF CANCER
- B7-H3 is a potent inhibitor of human T-cell activation: No evidence for B7-H3 and TREML2 interaction
- (2009) Judith Leitner et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma
- (2009) Henry S. Friedman et al. JOURNAL OF CLINICAL ONCOLOGY
- Imaging of integrin αvβ3 expression in patients with malignant glioma by [18F] Galacto-RGD positron emission tomography
- (2009) Oliver Schnell et al. NEURO-ONCOLOGY
- Vaccination Elicits Correlated Immune and Clinical Responses in Glioblastoma Multiforme Patients
- (2008) C. J. Wheeler et al. CANCER RESEARCH
- TGFβ in Cancer
- (2008) Joan Massagué CELL
- Radiation sensitization of glioblastoma by cilengitide has unanticipated schedule-dependency
- (2008) Tom Mikkelsen et al. INTERNATIONAL JOURNAL OF CANCER
- Phase I Clinical Trial of Cilengitide in Children With Refractory Brain Tumors: Pediatric Brain Tumor Consortium Study PBTC-012
- (2008) Tobey J. MacDonald et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized Phase II Study of Cilengitide, an Integrin-Targeting Arginine-Glycine-Aspartic Acid Peptide, in Recurrent Glioblastoma Multiforme
- (2008) David A. Reardon et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Trial of Single-Agent Bevacizumab Followed by Bevacizumab Plus Irinotecan at Tumor Progression in Recurrent Glioblastoma
- (2008) Teri N. Kreisl et al. JOURNAL OF CLINICAL ONCOLOGY
- B7-H4 is preferentially expressed in non-dividing brain tumor cells and in a subset of brain tumor stem-like cells
- (2008) Yu Yao et al. JOURNAL OF NEURO-ONCOLOGY
- Possible involvement of the M2 anti-inflammatory macrophage phenotype in growth of human gliomas
- (2008) Y Komohara et al. JOURNAL OF PATHOLOGY
- An Integrated Genomic Analysis of Human Glioblastoma Multiforme
- (2008) D. W. Parsons et al. SCIENCE
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started